These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 7887063)
1. p53 immunostaining as a marker of malignancy in cytologic preparations of body fluids. Tiniakos DG; Healicon RM; Hair T; Wadehra V; Horne CH; Angus B Acta Cytol; 1995; 39(2):171-6. PubMed ID: 7887063 [TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of immunohistochemical detection of p53 protein in pleural effusion and bronchial specimen.]. Wang J; Jiang Y; He A Zhongguo Fei Ai Za Zhi; 1998 Jul; 1(1):40-1. PubMed ID: 20863463 [TBL] [Abstract][Full Text] [Related]
3. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells. Walts AE; Said JW; Koeffler HP Mod Pathol; 1994 May; 7(4):462-8. PubMed ID: 8066074 [TBL] [Abstract][Full Text] [Related]
4. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Dowell SP; Wilson PO; Derias NW; Lane DP; Hall PA Cancer Res; 1994 Jun; 54(11):2914-8. PubMed ID: 8187077 [TBL] [Abstract][Full Text] [Related]
5. Improved detection of adenocarcinoma of serous fluids with p53 immunocytochemistry. Saleh HA; Bober P; Tabaczka P Acta Cytol; 1998; 42(6):1330-5. PubMed ID: 9850638 [TBL] [Abstract][Full Text] [Related]
7. Polyoma virus-associated cellular changes in the urine and bladder biopsy samples: a cytohistologic correlation. Herawi M; Parwani AV; Chan T; Ali SZ; Epstein JI Am J Surg Pathol; 2006 Mar; 30(3):345-50. PubMed ID: 16538054 [TBL] [Abstract][Full Text] [Related]
8. Image analysis and flow cytometric DNA studies of benign and malignant body cavity fluids: reappraisal of the role of current methods in the differential diagnosis of reactive versus malignant conditions. Lazcano O; Chen LM; Tsai C; Li CY; Katzmann JA; Sebo TJ; Kimlinger TK; Baker J Mod Pathol; 2000 Jul; 13(7):788-96. PubMed ID: 10912939 [TBL] [Abstract][Full Text] [Related]
10. Expression of glutathione-S-transferases isoenzymes and p53 in exfoliated human bladder cancer cells. Oğuztüzün S; Sezgin Y; Yazıcı S; Fırat P; Ozhavzalı M; Ozen H Urol Oncol; 2011; 29(5):538-44. PubMed ID: 19926314 [TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical detection of p53 protein as an adjunct in cytologic diagnosis from pancreatic duct brushings in mucin-producing tumors of the pancreas. Iwao T; Tsuchida A; Hanada K; Eguchi N; Kajiyama G; Shimamoto F Cancer; 1997 Jun; 81(3):163-71. PubMed ID: 9196015 [TBL] [Abstract][Full Text] [Related]
12. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Burstein DE; Reder I; Weiser K; Tong T; Pritsker A; Haber RS Mod Pathol; 1998 Apr; 11(4):392-6. PubMed ID: 9578091 [TBL] [Abstract][Full Text] [Related]
13. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity. Prayson RA Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291 [TBL] [Abstract][Full Text] [Related]
14. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications. Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956 [TBL] [Abstract][Full Text] [Related]
15. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Awadallah NS; Shroyer KR; Langer DA; Torkko KC; Chen YK; Bentz JS; Papkoff J; Liu W; Nash SR; Shah RJ Pancreas; 2008 Mar; 36(2):200-6. PubMed ID: 18376314 [TBL] [Abstract][Full Text] [Related]
16. Significance of psammoma bodies in serous cavity fluid: a cytopathologic analysis. Parwani AV; Chan TY; Ali SZ Cancer; 2004 Apr; 102(2):87-91. PubMed ID: 15098252 [TBL] [Abstract][Full Text] [Related]
17. Telomerase activity in benign and malignant cytologic fluids. Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600 [TBL] [Abstract][Full Text] [Related]
18. Increased p53 protein expression in malignant mammary phyllodes tumors. Tse GM; Putti TC; Kung FY; Scolyer RA; Law BK; Lau TS; Lee CS Mod Pathol; 2002 Jul; 15(7):734-40. PubMed ID: 12118111 [TBL] [Abstract][Full Text] [Related]
19. p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells. Mullick SS; Green LK; Ramzy I; Brown RW; Smith D; Gondo MM; Cagle PT Acta Cytol; 1996; 40(5):855-60. PubMed ID: 8842156 [TBL] [Abstract][Full Text] [Related]
20. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. Nagao T; Sugano I; Ishida Y; Hasegawa M; Matsuzaki O; Konno A; Kondo Y; Nagao K Cancer; 1998 Feb; 82(3):439-47. PubMed ID: 9452259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]